CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front
The Cancer Research Institute is shining a light on the explosive growth of cell therapies in the clinic, spotlighting China’s virtual overnight success in grabbing a lead role in the field. And they’re asking the world’s cancer drug development companies to adopt a new approach that will help the industry manage a finite number of potential trial patients while pointing researchers to the most likely avenue for doing something important — rather than just frittering away badly needed resources.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters